Nasdaq Approves Listing of Canary’s Staked Injective ETF

The significance here is less the ticker than the structure: a staked product with a disclosed 1.10% sponsor fee sets a visible cost benchmark for yield-bearing single-asset ETFs, a category still working out how staking rewards and fees are split. It matters most for issuers racing to wrap proof-of-stake tokens and for allocators weighing staking exposure against the drag of the fee. Whether the 90% staking threshold becomes a template, and how the fee compares with rival filings, is the open question worth watching.